Key result
Maternal hypertensive disorder deaths in China fell ~88% between 1990 and 2021.
Why the study?
The burden and quality of care associated with maternal hypertensive disorders in China over time and across age groups from 1990 to 2021 were not well characterized.
Observational
Effect estimate: AAPC -7.31 (95% CI -7.81 to -6.80)
Absolute Event Rate: 0.03% vs 0.24%
The overall burden of maternal hypertensive disorders in China has significantly declined from 1990 to 2021, though the burden has shifted toward older maternal age groups.
Decline in maternal hypertensive disorder mortality indicates progress in China; leaves open drivers of age shifts and 2035 projections.
Objectives: This study aims to analyze the disease burden and quality of care associated with maternal hypertensive disorders in China over time and across age groups from 1990 to 2021. Methods: This study employs statistical methods, including joinpoint regression analysis, decomposition analysis, age-period-cohort analysis, and the quality-of-care index, to assess the disease burden of maternal hypertensive disorders in China between 1990 and 2021. It uses an ARIMA model to forecast the disease burden for the period 2022– 2035. Results: Compared with 1990, the decline in the number of deaths, death rate, number of DALYs, and DALYs rate in 2021 was over 80% in each case, at 89.66%, 87.50%, 84.97% and 82.97%, respectively; the decline in the number and rate of prevalence, as well as the number and rate of incidence, ranged between 35% and 45%. The burden of disease has shifted from the 20– 24 age group to the 30– 34 age group (peak in number of cases) or the 25– 29 age group (peak in rates). ARIMA forecasts that these rates will continue to decline through to 2035, although the rate of decline in incidence and prevalence will slow. The quality-of-care index rose steadily from 2003 to 2021. Conclusion: The overall burden of maternal hypertensive disorders in China is declining. Based on the observed epidemiological trends: the quality of care is relatively low among both younger and older age groups; blood pressure management across the entire reproductive lifespan could be optimized in the future.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted an observational in Maternal hypertensive disorders. Time period (2021 vs 1990) vs. 1990 baseline was evaluated on Age-standardized death rate (per 100,000) (AAPC -7.31, 95% CI -7.81 to -6.80). Between 1990 and 2021, the age-standardized death rate from maternal hypertensive disorders in China declined by 87.50%, with an average annual percentage change of -7.31.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: